Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population

Bozaoglu, Kiymet, Segal, David, Shields, Katherine A., Cummings, Nick, Curran, Joanne E., Comuzzie, Anthony G., Mahaney, Michael C., Rainwater, David L., VandeBerg, John L., MacCluer, Jean W., Collier, Greg, Blangero, John, Walder, Ken and Jowett, Jeremy B.M. 2009, Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population, The Journal of Clinical Endocrinology & Metabolism, vol. 94, no. 8, pp. 3085-3088.

Attached Files
Name Description MIMEType Size Downloads

Title Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population
Author(s) Bozaoglu, Kiymet
Segal, David
Shields, Katherine A.
Cummings, Nick
Curran, Joanne E.
Comuzzie, Anthony G.
Mahaney, Michael C.
Rainwater, David L.
VandeBerg, John L.
MacCluer, Jean W.
Collier, Greg
Blangero, John
Walder, Ken
Jowett, Jeremy B.M.
Journal name The Journal of Clinical Endocrinology & Metabolism
Volume number 94
Issue number 8
Start page 3085
End page 3088
Total pages 4
Publisher The Endocrine Society
Place of publication Philadelphia, PA
Publication date 2009-08
ISSN 0021-972X
1945-7197
Keyword(s) BMI
Body mass index
HDL
high-density lipoprotein
ND
nondiabetic
T2D
type 2 diabetes
Summary Context: Chemerin is a novel adipokine previously associated with metabolic syndrome phenotypes in a small sample of subjects from Mauritius. Objective: The aim of the study was to determine whether plasma chemerin levels were associated with metabolic syndrome phenotypes in a larger sample from a second, unrelated human population. Design, Setting, Patients, and Intervention: Plasma samples were obtained from the San Antonio Family Heart Study (SAFHS), a large family-based genetic epidemiological study including 1431 Mexican-American individuals. Individuals were randomly sampled without regard to phenotype or disease status. This sample is well-characterized for a variety of phenotypes related to the metabolic syndrome. Main Outcomes: Plasma chemerin levels were measured by sandwich ELISA. Linear regression and correlation analyses were used to determine associations between plasma chemerin levels and metabolic syndrome phenotypes. Results: Circulating chemerin levels were significantly higher in nondiabetic subjects with body mass index (BMI) greater than 30 kg/m2 compared with those with a BMI below 25 kg/m2 (P < 0.0001). Plasma chemerin levels were significantly associated with metabolic syndrome-related parameters, including BMI (P < 0.0001), fasting serum insulin (P < 0.0001), triglycerides (P < 0.0001), and high-density lipoprotein cholesterol (P = 0.00014), independent of age and sex in nondiabetic subjects. Conclusion: Circulating chemerin levels were associated with metabolic syndrome phenotypes in a second, unrelated human population. This replicated result using a large human sample suggests that chemerin may be involved in the development of the metabolic syndrome.
Language eng
Field of Research 060104 Cell Metabolism
Socio Economic Objective 920104 Diabetes
HERDC Research category C1 Refereed article in a scholarly journal
HERDC collection year 2009
Copyright notice ©2009, The Endocrine Society
Persistent URL http://hdl.handle.net/10536/DRO/DU:30019918

Document type: Journal Article
Collections: School of Medicine
Open Access Checking
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 75 times in TR Web of Science
Scopus Citation Count Cited 85 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 426 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Fri, 25 Sep 2009, 10:09:57 EST by Sally Morrigan

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.